You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
P109 Utility of skin biopsy in patients with systemic lupus erythematosus
  1. Catherine Grace Hobayan1,
  2. Abraham Korman2 and
  3. Judith Lin3
  1. 1College of Medicine, The Ohio State University, Columbus, Ohio, USA
  2. 2Dept. of Dermatology, The Ohio State University, Columbus, Ohio, USA
  3. 3Division of Rheumatology and Immunology, Dept. of Internal Medicine, The Ohio State University, Columbus, Ohio, USA

Abstract

Objective The objective of this study was to determine the utility of skin biopsy in patients presenting with a rash concerning for systemic lupus erythematosus (SLE) to see if biopsy results are different from clinical diagnoses made by rheumatologists or dermatologists and changed management. The results of this study would help determine whether skin biopsy should be integrated into the workflow of patients undergoing workup for new presentation of SLE or in cases with known SLE but unclear if the rash is related.

Methods Patients with connective tissue diseases seen by rheumatology and dermatology who had a skin biopsy for a rash between 2015–2022 at a single institution were identified. Of these, 48 patients were assigned a clinical diagnosis of SLE and therefore selected for retrospective chart review. Collected data include skin biopsy results and changes in medical treatments.

Results In 27.1% of all cases in this study, biopsy results were discordant from clinical diagnosis; out of these cases, 69.7% of patients’ medication regimens were changed following receipt of skin biopsy results. For instance, biopsy results showing psoriasiform findings led to addition of methotrexate or apremilast. Biopsy results were concordant with clinical diagnosis in 72.9% of all cases in this study; out of these cases, only 34.3% of patients’ medication regimens were changed following skin biopsy. These changes involved increasing the number or dosage of immunosuppressive medications such as hydroxychloroquine and dapsone.

Conclusion Most patients presenting with a rash concerning for SLE are diagnosed clinically, and data on skin biopsy is limited. Of patients who underwent skin biopsy, biopsy results often supported the clinical diagnosis, but a different diagnosis was suggested on biopsy in 27% of cases, thus impacting management. Skin biopsy should be integrated in cases of clinical ambiguity.

Acknowledgements This study was approved by the Institutional Review Board of the Ohio State University (#2023E0927) and supported by Award #UL1TR002733 from the National Center for Advancing Translational Sciences (NCATS). The content is solely the responsibility of the authors and does not necessarily represent the official views of NCATS or the National Institutes of Health.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

https://doi.org/10.1136/lupus-2024-el.163

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.